Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| General Surgery | 10 | 2024 | 1692 | 2.840 |
Why?
|
| Internship and Residency | 13 | 2024 | 5879 | 2.080 |
Why?
|
| Retirement | 3 | 2021 | 197 | 1.440 |
Why?
|
| Financial Management | 2 | 2022 | 160 | 1.340 |
Why?
|
| Appendiceal Neoplasms | 2 | 2019 | 155 | 1.120 |
Why?
|
| Clinical Competence | 6 | 2024 | 4786 | 1.110 |
Why?
|
| Appendicitis | 3 | 2023 | 675 | 0.940 |
Why?
|
| Education, Medical, Graduate | 4 | 2024 | 2372 | 0.770 |
Why?
|
| Colon, Transverse | 1 | 2021 | 24 | 0.750 |
Why?
|
| Operating Room Technicians | 1 | 2019 | 15 | 0.650 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2024 | 928 | 0.650 |
Why?
|
| Professional Practice | 1 | 2020 | 313 | 0.630 |
Why?
|
| Specialties, Surgical | 2 | 2020 | 389 | 0.620 |
Why?
|
| Surgical Stapling | 1 | 2019 | 98 | 0.620 |
Why?
|
| Masks | 1 | 2021 | 208 | 0.620 |
Why?
|
| Mentors | 2 | 2021 | 663 | 0.620 |
Why?
|
| Education, Distance | 1 | 2021 | 260 | 0.580 |
Why?
|
| Biomedical Research | 2 | 2024 | 3429 | 0.560 |
Why?
|
| Teaching Rounds | 1 | 2021 | 276 | 0.550 |
Why?
|
| Imidazoles | 6 | 2005 | 1173 | 0.530 |
Why?
|
| Catheterization, Central Venous | 1 | 2021 | 526 | 0.520 |
Why?
|
| Myocardial Stunning | 3 | 2004 | 67 | 0.510 |
Why?
|
| Physicians, Women | 1 | 2020 | 510 | 0.470 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 561 | 0.470 |
Why?
|
| Cardiotonic Agents | 3 | 2006 | 540 | 0.450 |
Why?
|
| Occupational Health | 1 | 2020 | 807 | 0.440 |
Why?
|
| Ischemic Preconditioning, Myocardial | 4 | 2005 | 69 | 0.410 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3094 | 0.400 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3216 | 0.400 |
Why?
|
| Boston | 5 | 2024 | 9324 | 0.380 |
Why?
|
| Pyridines | 6 | 2005 | 2872 | 0.350 |
Why?
|
| Education, Medical | 1 | 2022 | 1725 | 0.350 |
Why?
|
| Laparoscopy | 1 | 2021 | 2030 | 0.330 |
Why?
|
| Receptors, Purinergic P1 | 2 | 2005 | 108 | 0.310 |
Why?
|
| Pandemics | 4 | 2021 | 8663 | 0.310 |
Why?
|
| Appendectomy | 3 | 2023 | 433 | 0.290 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 5427 | 0.270 |
Why?
|
| Abscess | 2 | 2019 | 605 | 0.250 |
Why?
|
| Myocardial Reperfusion Injury | 3 | 2006 | 480 | 0.240 |
Why?
|
| Adenosine A1 Receptor Agonists | 1 | 2004 | 13 | 0.240 |
Why?
|
| Adenosine A2 Receptor Agonists | 1 | 2004 | 31 | 0.240 |
Why?
|
| Bradycardia | 1 | 2005 | 298 | 0.220 |
Why?
|
| Guanidines | 1 | 2004 | 194 | 0.220 |
Why?
|
| Pyruvates | 1 | 2003 | 83 | 0.220 |
Why?
|
| Faculty, Medical | 2 | 2023 | 1205 | 0.210 |
Why?
|
| Purinergic P1 Receptor Agonists | 4 | 2006 | 39 | 0.210 |
Why?
|
| Educational Measurement | 2 | 2020 | 1251 | 0.200 |
Why?
|
| Attitude of Health Personnel | 3 | 2021 | 3882 | 0.200 |
Why?
|
| Professional Autonomy | 1 | 2023 | 171 | 0.200 |
Why?
|
| Sulfones | 1 | 2004 | 448 | 0.190 |
Why?
|
| Vasodilation | 1 | 2005 | 966 | 0.190 |
Why?
|
| History, 17th Century | 1 | 2021 | 108 | 0.190 |
Why?
|
| Humans | 24 | 2024 | 761098 | 0.180 |
Why?
|
| Coronary Circulation | 2 | 2004 | 1611 | 0.180 |
Why?
|
| History, 18th Century | 1 | 2021 | 206 | 0.180 |
Why?
|
| Personnel Turnover | 1 | 2020 | 88 | 0.180 |
Why?
|
| Academic Medical Centers | 2 | 2020 | 2757 | 0.170 |
Why?
|
| United States | 6 | 2024 | 72337 | 0.160 |
Why?
|
| Practice Management, Medical | 1 | 2020 | 191 | 0.160 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2019 | 3770 | 0.160 |
Why?
|
| History, 19th Century | 1 | 2021 | 718 | 0.160 |
Why?
|
| Myocardium | 3 | 2006 | 4746 | 0.150 |
Why?
|
| Specialty Boards | 1 | 2020 | 235 | 0.150 |
Why?
|
| Intraoperative Period | 1 | 2019 | 510 | 0.150 |
Why?
|
| Acute Disease | 4 | 2023 | 7240 | 0.150 |
Why?
|
| Evaluation Studies as Topic | 1 | 2020 | 1624 | 0.150 |
Why?
|
| Career Mobility | 1 | 2020 | 259 | 0.150 |
Why?
|
| Efficiency | 1 | 2021 | 476 | 0.150 |
Why?
|
| Anastomosis, Surgical | 1 | 2021 | 982 | 0.140 |
Why?
|
| Organizational Culture | 1 | 2020 | 509 | 0.140 |
Why?
|
| Myocardial Infarction | 5 | 2005 | 11475 | 0.140 |
Why?
|
| Receptor, Adenosine A1 | 3 | 2005 | 42 | 0.140 |
Why?
|
| Male | 18 | 2024 | 360675 | 0.140 |
Why?
|
| Models, Educational | 1 | 2019 | 373 | 0.130 |
Why?
|
| Female | 13 | 2024 | 392458 | 0.120 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 4 | 2006 | 681 | 0.120 |
Why?
|
| History, 21st Century | 1 | 2021 | 1566 | 0.120 |
Why?
|
| Self Concept | 1 | 2020 | 1046 | 0.120 |
Why?
|
| Focus Groups | 1 | 2020 | 1409 | 0.110 |
Why?
|
| Palliative Care | 2 | 2021 | 3593 | 0.110 |
Why?
|
| Career Choice | 1 | 2020 | 757 | 0.110 |
Why?
|
| Publishing | 1 | 2021 | 832 | 0.110 |
Why?
|
| Income | 1 | 2022 | 1868 | 0.110 |
Why?
|
| Family | 1 | 2024 | 3193 | 0.110 |
Why?
|
| History, 20th Century | 1 | 2021 | 2764 | 0.110 |
Why?
|
| Emergency Treatment | 1 | 2016 | 495 | 0.100 |
Why?
|
| Infection Control | 1 | 2020 | 983 | 0.100 |
Why?
|
| Operating Rooms | 1 | 2019 | 790 | 0.100 |
Why?
|
| Heart | 1 | 2005 | 4431 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2006 | 1240 | 0.090 |
Why?
|
| Myocardial Ischemia | 3 | 2006 | 2133 | 0.090 |
Why?
|
| Program Evaluation | 1 | 2019 | 2487 | 0.090 |
Why?
|
| Veterans | 1 | 2024 | 2652 | 0.090 |
Why?
|
| Perioperative Care | 1 | 2017 | 1037 | 0.080 |
Why?
|
| Adenosine A1 Receptor Antagonists | 2 | 2005 | 27 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 39121 | 0.070 |
Why?
|
| Triazines | 2 | 2006 | 311 | 0.070 |
Why?
|
| Adult | 4 | 2024 | 221083 | 0.070 |
Why?
|
| Massachusetts | 1 | 2020 | 8836 | 0.070 |
Why?
|
| Adenosine A2 Receptor Antagonists | 1 | 2006 | 49 | 0.070 |
Why?
|
| Aging | 1 | 2005 | 8701 | 0.070 |
Why?
|
| Caveolin 3 | 1 | 2006 | 24 | 0.070 |
Why?
|
| Premedication | 1 | 2006 | 246 | 0.060 |
Why?
|
| Swine | 3 | 2004 | 5909 | 0.060 |
Why?
|
| Curriculum | 1 | 2019 | 3739 | 0.060 |
Why?
|
| Aged | 4 | 2021 | 169266 | 0.060 |
Why?
|
| Rats, Inbred F344 | 1 | 2005 | 826 | 0.060 |
Why?
|
| Caveolin 1 | 1 | 2006 | 255 | 0.060 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2004 | 128 | 0.060 |
Why?
|
| Triazoles | 2 | 2006 | 903 | 0.060 |
Why?
|
| Neutrophil Activation | 1 | 2004 | 180 | 0.060 |
Why?
|
| Partial Pressure | 1 | 2003 | 245 | 0.050 |
Why?
|
| Adenosine | 2 | 2005 | 805 | 0.050 |
Why?
|
| Sus scrofa | 1 | 2004 | 428 | 0.050 |
Why?
|
| Bicarbonates | 1 | 2003 | 292 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2021 | 80673 | 0.050 |
Why?
|
| Nitric Oxide Synthase | 1 | 2005 | 908 | 0.050 |
Why?
|
| Rats | 6 | 2006 | 23713 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2023 | 54419 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2004 | 1756 | 0.040 |
Why?
|
| Perfusion | 1 | 2004 | 1390 | 0.040 |
Why?
|
| Carbon Dioxide | 1 | 2003 | 1148 | 0.040 |
Why?
|
| Sodium | 1 | 2003 | 1589 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2005 | 1480 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2006 | 8164 | 0.040 |
Why?
|
| Animals | 10 | 2006 | 168083 | 0.040 |
Why?
|
| Cholesterol | 1 | 2006 | 2902 | 0.030 |
Why?
|
| Subcellular Fractions | 2 | 2006 | 525 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2004 | 18217 | 0.030 |
Why?
|
| Neutrophils | 1 | 2004 | 3763 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2017 | 1436 | 0.020 |
Why?
|
| Enzyme Inhibitors | 3 | 2005 | 3700 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2004 | 5662 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2017 | 2981 | 0.020 |
Why?
|
| Centrifugation, Density Gradient | 1 | 2006 | 298 | 0.020 |
Why?
|
| Middle Aged | 1 | 2020 | 220835 | 0.020 |
Why?
|
| Sucrose | 1 | 2006 | 158 | 0.020 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 2005 | 45 | 0.020 |
Why?
|
| Butadienes | 1 | 2005 | 107 | 0.020 |
Why?
|
| Xanthines | 1 | 2005 | 120 | 0.010 |
Why?
|
| Oxidants | 1 | 2005 | 169 | 0.010 |
Why?
|
| Cell Compartmentation | 1 | 2004 | 383 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2016 | 10083 | 0.010 |
Why?
|
| Length of Stay | 1 | 2017 | 6420 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2005 | 517 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 471 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 475 | 0.010 |
Why?
|
| Patient Readmission | 1 | 2017 | 3268 | 0.010 |
Why?
|
| Heart Rate | 2 | 2004 | 4196 | 0.010 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2005 | 613 | 0.010 |
Why?
|
| Quality Improvement | 1 | 2017 | 3801 | 0.010 |
Why?
|
| Hydrogen Peroxide | 1 | 2005 | 731 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2006 | 1682 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2023 | 64670 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2006 | 2048 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2006 | 3577 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2023 | 20600 | 0.010 |
Why?
|
| Nitriles | 1 | 2005 | 971 | 0.010 |
Why?
|
| Blood Pressure | 2 | 2004 | 8478 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 15845 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2006 | 5033 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 20120 | 0.010 |
Why?
|
| Reperfusion Injury | 1 | 2005 | 1026 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2004 | 4849 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2006 | 3665 | 0.010 |
Why?
|
| Myocytes, Cardiac | 1 | 2005 | 1666 | 0.010 |
Why?
|
| Prognosis | 1 | 2016 | 29672 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2016 | 24013 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2017 | 15634 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 6305 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2005 | 3114 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 2004 | 3111 | 0.010 |
Why?
|
| Time Factors | 2 | 2005 | 39953 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 2005 | 3812 | 0.010 |
Why?
|
| Ventricular Function, Left | 1 | 2004 | 3899 | 0.010 |
Why?
|
Concepts
(175)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(11)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_